Wuhan Renfulikang Pharmaceutical Co., Ltd.

1. Explore the recommended dose of HW021199 tablets for the treatment of idiopathic pulmonary fibrosis; 2. Preliminary evaluation of the efficacy and safety of HW021199 tablets in the treatment of idiopathic pulmonary fibrosis; 3. Evaluate the pharmacokinetic and pharmacodynamic characteristics of HW021199 tablets in patients with idiopathic pulmonary fibrosis.

The main purpose of the study is to evaluate the bioequivalence of the test preparation and the reference preparation by taking a single oral dose of Mirabegron sustained-release tablets (50 mg, test preparation) produced by Wuhan Renfu Likang Pharmaceutical Co., Ltd. and Mirabegron sustained-release tablets (trade name: Myrbetriq ®, 50 mg, reference preparation) produced by Astellas Pharma Global Development Inc. in healthy subjects under fasting state. Secondary purpose of the study is to evaluate the safety of the test preparation and reference preparation of Mirabegron sustained-release tablets after a single oral dose in Chinese healthy subjects under fasting state.

The main purpose of the study is to study the pharmacokinetics of the test preparation Arbidol Hydrochloride Tablets (specification: 50 mg/tablet) and the reference preparation Arbidol Hydrochloride Tablets (Арбидол®, specification: 50 mg/tablet, produced by Ｆаｒｍｓｔａｎｄａｒｔ-Ｌｅкｓｒｅｄｓｔвａ) in healthy subjects after a single oral administration in the fed state, and to evaluate the bioequivalence of the two preparations after oral administration in the fed state. Secondary purpose of the study: to study the safety of the test preparation Arbidol Hydrochloride Tablets 50 mg and the reference preparation Arbidol Hydrochloride Tablets "Арбидол®" 50 mg in healthy subjects.